Clinical curative effect and safety of Silybin-nanosuspension in the treatment of liver tumor
10.3969/j.issn.1005-1678.2016.08.028
- VernacularTitle:水飞蓟宾纳米混悬剂对肝脏恶性肿瘤患者的临床疗效及安全性
- Author:
Jun LIU
;
Chunliang GUO
;
Lu ZHANG
- Publication Type:Journal Article
- Keywords:
Silybin-nanosuspension;
hepatic malignancies;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(8):105-107
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy and safety of Silybin-nanosuspension in the treatment of liver cancer.Methods 56 patients with liver tumor were collected from February 2014 to May 2015 in our hospital,and all patients were randomly divided into treatment group(n=24)and control group(n=32).The treatment group was treated with oral Silybin-nanosuspension 360mg(Silybin)and control group was treated with Silybin capsule 360mg(Silybin),once a day.The treatment was over once the following conditions appear,the disease progression,or intolerable toxicity,or the lesion site can be treat with surgery,or patient death.Evaluating the efficacy through comparing the data of objective response rate,disease control rate, progression-free survival and overall survival,and record the adverse reactions through measuring the values of indicators of blood toxicity ( leukocytes, neutrophils,platelets and hemoglobin ) and the liver function parameters ( Valley alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase) .Results The objective response rate, disease control rate, progression-free survival and overall survival of treatment group were significantly better than control group(P<0.05),and the parameters of blood toxicity and liver function were no significant differences.Conclusion The Silybin-nanosuspension is safe and effective for the treatment of liver malignancies.
